New Clinical Evidence Continues to Support the Effectiveness and Value of AMNIOX Medical Products

ATLANTA–(BUSINESS WIRE)–AMNIOX Medical, Inc., a TissueTech, Inc. company, announced today that nine clinical posters demonstrating the effectiveness of NEOX^® Wound Allograft – Amniox’s proprietary cryopreserved Umbilical Cord and Amniotic Membrane (UC/AM) product for chronic wound management – were presented at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Meeting. The meeting was held at the San Diego Convention Center in San Diego, California, from April 5-9.

Following peer review, all nine posters were accepted for presentation at the symposium. These posters present therapeutic and surgical applications of NEOX Wound Allograft in a range of severe wound types that are resistant to the current standard of care. These wounds include wounds resulting from radiation therapy; wounds due to Charcot arthropathy; severe burns; trauma wounds; chronic non-healing ulcers; skin grafts and wounds post-treatment for Basal Cell Carcinoma. With all of these complex, hard-to-heal cases, patients achieved closure of their wounds subsequent to applications of NEOX, including a number of situations where these patients had failed other advanced therapies.

“The posters presented at SAWC highlight NEOX’s clinical effectiveness and value in a variety of wounds that are difficult to treat with typical wound care modalities,” said Thomas J. Dugan, Chief Executive Officer of Amniox Medical. “Across all of this clinical experience, patients treated with NEOX experienced closure of hard-to-heal wounds. The strength of this clinical evidence continue to drive demand for unique regenerative properties of umbilical cord tissue.”

Studies presented at SAWC included the following posters:

• Cryopreserved Umbilical Cord* (cUC) Treatment of Radiation Wound Post Melanoma Removal Involving Soft Tissue and Bone, David F. Fernandez, MD
• Injectable Lyophilized Human Umbilical Cord and Amniotic Membrane (UC/AM) as an Interventional Treatment in Early Charcot Foot Presentation, Wayne J. Caputo, DPM
• Use of Cryopreserved Umbilical Cord as Adjunctive Therapy for Multiple Burn Wounds of the Lower Extremity, Kimberly Jackman, MD, and Leslie Harris, APRN
• Cryopreserved Umbilical Cord * (cUC) Use for Acute Orthopedic Trauma Wounds, Kaitlyn Griffin, BS and Christopher Stewart, MD
• Combination of Cryopreserved Umbilical Cord (cUC)* with Negative Pressure Therapy for the Treatment of Chronic Non-Healing Ulcers, Allen Raphael, DPM
• The Use of Cryopreserved Umbilical Cord/Amniotic Membrane (cUC) to Generate Granulation Tissue over Scalp Post Basal Cell Carcinoma (BCC) Removal in Order to Prep for a Split-thickness Skin Graft, Charles L. Dupin, MD, Meghan Bias, MD, Amanda Gregoire, NP and Renata Falgout, RN
• The Use of Cryopreserved Human Amniotic Membrane and Umbilical Cord (AM/UC) Allografts to Expedite Healing in Patients with Chronic Non-healing Wounds, Justin Goldsmith, DPM, Aamir Mahmood, DPM, Patrick Sanchez, DPM, Anna Tien, DPM, Sarah Park, DPM, Jake Ruff, DPM, Andrea Seat, DPM, Michael Czurylo, DPM, Laith Shaman, DPM and Matthew Garoufalis, DPM, FASPS, FACFAOM, CWS
• The Use of Cryopreserved Human Umbilical Cord in the treatment of an Irradiated Tissue Wound Post Treatment for Basal Cell Carcinoma, Amesh Patel, MD, and Carolyn Hewett, RN, CWOCN
• Surgical Implantation Technique for Treating Chronic Ulcers with Cryopreserved Umbilical Cord*, Allen Raphael, DPM

Amniox parent TissueTech pioneered the commercialization and clinical application of human umbilical cord and amniotic membrane to promote regenerative healing. In utero, wound healing occurs rapidly and with minimal scar. This restorative ability is innate to these placental tissues and can be preserved and transplanted to adults. Heavy chain hyaluronic acid/pentraxin-3 (HC-HA/PTX3) is the key protein complex present in these tissues to orchestrate that regenerative healing process.

Amniox Medical is the first provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. Amniox utilizes its proprietary CRYOTEK^TM process, a cryopreservation technology that preserves the biological and structural integrity of these tissues more effectively than other available technologies. Since inception, more than 300,000 human transplants of its products have been performed and more than 300 peer-reviewed studies supporting its technology platform have been published.

About Amniox Medical, Inc.

Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CryoTek technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit http://www.amnioxmedical.com

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue^®, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; Bio-Tissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) have supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft^®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.